SCHEMBL4601098

SCHEMBL4601098

CCc1ccc(C)n(C)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.35
NPEPPS P55786 2/20 0.34
CTRC Q99895 1/20 0.33
CSF1R P07333 1/20 0.33
MGLL Q99685 1/20 0.32
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
HTT P42858 1/20 0.32
PKM P14618 1/20 0.32
ATM Q13315 1/20 0.32
KDM4E B2RXH2 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
CRBN Q96SW2 1/20 0.31
USP2 O75604 1/20 0.31
BRPF1 P55201 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11148316 0.83 IDH1 (0.33) IDH1KDM4EL3MBTL1BRPF1
SCHEMBL13171703 0.79 GABRA1 (0.35) IDH1L3MBTL1DAOTDP1
SCHEMBL12125050 0.76 KDM4E (0.43) CTRCKDM4EL3MBTL1USP2TDP1
SCHEMBL12180573 0.73 BRPF1 (0.38) HTTKDM4EL3MBTL1CRBNUSP2
SCHEMBL22461725 0.71 KMT2A (0.37) IDH1GRIN1GRIN2BKDM4EL3MBTL1
SCHEMBL4136703 0.70 KDM4E (0.33) IDH1KDM4EL3MBTL1CRBN
SCHEMBL21978984 0.70 GRIA1 (0.37) IDH1KDM4ETDP1
SCHEMBL2114603 0.70 HPGD (0.33) HTTKDM4EL3MBTL1CRBNUSP2
SCHEMBL15804043 0.70 ATAD2 (0.38) HTTATMKDM4EL3MBTL1CRBN
SCHEMBL12049599 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841455-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors ARRAY BIOPHARMA INC. (US) 2014-09-23 US disclosed
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors ARRAY BIOPHARMA INC. (US) 2012-10-11 US disclosed
EP-1802578-B1 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-04-23 EP disclosed
EP-1802578-A1 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS Sanofi-Aventis Deutschland GmbH (DE) 2007-07-04 EP disclosed
WO-2006042638-A1 3,6-SUBSTITUTED 5-ARYLAMINO-1H-PYIDINE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS IN THE TREATMENT OF TISSUE DAMAGE OR DISEASE CAUSED BY NECROSIS OR APOPTOSIS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258952-A1 Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors AFF1, FLI1, F3 IDH1 764/4885NPEPPS 2549/4885CTRC 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.